TLR Adaptor Protein MYD88 Mediates Sensitivity to HDAC Inhibitors via a Cytokine-Dependent Mechanism Cancer Research – December 2016 New-et-al-Cancer-Research-2016
ASH-Dec-2016-Poster-2
ASH-Dec-2016-Poster-1
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2) Lancet – November 2016 Kerr-et-al-Lancet-Oncology-2016-
ESMO-2016-Poster-1
Oxford, UK, 1st December 2015; Celleron Therapeutics, the UK-based company developing personalised medicine for cancer patients, has today announced that significant clinical activity was observed in the first human trial of its pioneering personalised cancer treatment CXD101 in patients at…
Evaluation of PIK3CA Mutation As a Predictor of Benefit From Nonsteroidal Anti-Inflammatory Drug Therapy in Colorectal Cancer. Journal of Clinical Oncology – December 2013 Domingo-et-al-JCO.2013.50
Tailoring treatment and trials to prognosis. Nature Reviews – August 2013 Kerr-and-Shi-Nature-Reviews.2013.97
Use of multivariate analysis to suggest a new molecular classification of colorectal cancer Journal of Pathology – 2013 Domingo_et_al-2013-The_Journal_of_Pathology
Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nature Reviews – October 2011 La-Thangue-and-Kerr-Nature-Reviews-2011